Effect of Glucose on QTc Interval in Type 1 Diabetes
Status:
Completed
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
High blood glucose levels (hyperglycaemia) and Moxifloxacin (a commonly used antibiotic) have
both been shown independently to affect heart activity in healthy volunteers as recorded by
ECG. i.e. Both cause prolongation of the QTc interval which is a measure of the time between
the start of the Qwave and the end of the Twave during a heartbeat cycle. In this study, the
investigators want to find out whether moxifloxacin and hyperglycaemia cause QTc prolongation
in Type 1 diabetic patients. The investigators also want to assess whether C-peptide (a
fragment if insulin normally found in the blood but not present in the blood of Type 1
diabetics) has the opposite effect on heart activity i.e it shortens the QTc interval will
reverse the effect of QTc prolongation in Type 1 diabetes as this may be useful for
preventing 'dead in bed' syndrome also known as 'Sudden Cardiac Death' which is more common
in diabetic patients compared to healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Richmond Pharmacology Limited Richmond Research Institute
Collaborator:
Richmond Pharmacology Limited
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination